EFFECT OF HEMODIALYSIS ON THE PHARMACOKINETICS OF CETIRIZINE

被引:16
作者
AWNI, WM
YEH, J
HALSTENSON, CE
OPSAHL, JA
CHUNG, M
MATZKE, GR
机构
[1] UNIV MINNESOTA,COLL PHARM,MINNEAPOLIS,MN 55455
[2] UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455
[3] PFIZER PHARMACEUT INC,NEW YORK,NY
关键词
Cetirizine; haemodialysis; pharmacokinetics; renal failure;
D O I
10.1007/BF00314806
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of Cetirizine, a histamine H1-receptor antagonist, were investigated in five renal failure patients undergoing chronic haemodialysis therapy. The patients received one 10 mg cetirizine dihydrochloride capsule 3 h before haemodialysis. Concentrations of cetirizine in serum and dialysate were determined by HPLC. The maximum serum cetirizine concentration and the time to reach that maximum were 285 μg·1-1 and 2.0 h, respectively. The terminal disposition half-life of cetirizine in these patients was 19.3 h. The haemodialysis clearance of cetirizine was 14.0 ml · min-1. Although this is approximately 33% of the apparent total body clearance of cetirizine in subjects with normal renal function, the fraction of the dose removed by dialysis was only 9.4%. Thus, since haemodialysis does not produce a clinically significantly alteration in cetirizine elimination, no supplemental dose should be necessary after dialysis. © 1990 Springer-Verlag.
引用
收藏
页码:67 / 69
页数:3
相关论文
共 5 条
[1]  
MADDOX DE, 1987, ANN ALLERGY, V59, P43
[2]  
MATZKE GR, 1987, ANN ALLERGY, V59, P25
[3]  
SIMONS FE, 1987, ANN ALLERGY, V59, P20
[4]  
SNYDER SH, 1987, ANN ALLERGY, V59, P4
[5]  
WOOD SG, 1987, ANN ALLERGY, V59, P31